CLEVELAND - Prostate cancer is the second leading cause of cancer-related deaths in men with an estimated 192,280 new cases diagnosed in the US in 2009 (Jemal 2009). Diet is considered one of the most ...

Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

In a recent comprehensive review published in Cyborg Bionic Systems, researchers led by Keyi Li from the General Hospital of Northern Theater Command in Shenyang, along with international ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced it has awarded two grants to organizations working to address disparities in biomarker testing for breast and prostate cancer ...

Researchers have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of ...

The Nuclear Medicine Department at Ridley-Tree Cancer Center (now part of Sutter Health) has announced greater capabilities to treat prostate cancer using the injectable radioligand therapy, Pluvicto ...

The Precision of Stereotactic Body Radiation Therapy (SBRT), an Advanced Treatment Technique, Enables Treatment in Five Days, Significantly Reducing the Time Men Must Spend Undergoing Care Prostate ...

Outranked only by skin cancer, prostate cancer is the second most common cancer in men in the U.S. Although one in every eight American men will be diagnosed with prostate cancer at some point, an ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.